Management standard of chronic bone disease for community hospitals

doi:10.3877/cma.j.issn.1674-134X.2023.01.001

Abstract

Abstract:

China is one of the countries with a rapid increase in the prevalence of skeletal diseases in the world. Skeletal diseases are an important cause of disability and labor incapacity in China. Some skeletal muscle diseases, especially degenerative bone joint diseases, have the characteristics of hidden pathogenesis, long course of disease, and difficulty in completely curing. At the same time, its awareness rate, consultation rate and control rate are still at a low level overall. 《Management standard of chronic bone disease for community hospital》 emphasizes that the defense line of chronic skeletal diseases is moving forward, and is aimed at the whole population, including healthy people, people who are prone to chronic skeletal diseases and patients with chronic skeletal diseases. It formulates a chronic skeletal disease health management path and evaluation system, and provides a full range of skeletal health management service guidance. The content includes disease introduction, epidemiology, screening and evaluation, dietary guidance, exercise intervention, psychological counseling, drug treatment, etc., and is scientific and easy to implement. It is convenient for grass-roots medical and health workers, health management workers and the public to practice. The regulation is an important measure to implement the Healthy China initiative and help promote standardization of prevention and control of chronic bone diseases.

Key words: Osteoarthritis, knee, Osteoporosis, Chronic disease, Primary disease prevention, Community health service

Joint Surgery Group of Chinese Orthopaedic Association., Shanghai Changzheng Hospital, Shanghai 200003, China. Management standard of chronic bone disease for community hospitals[J]. Chinese Journal of Joint Surgery(Electronic Edition), 2023, 17(01): 1-10.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhgjwkzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.1674-134X.2023.01.001

https://zhgjwkzz.cma-cmc.com.cn/EN/Y2023/V17/I01/1

Figures/Tables 2

References 30

[1]	杜鹏，陆杰华，何文炯. 新时代积极应对人口老龄化发展报告－2018, 2018[M]. 北京：华龄出版社，2018.
[2]	Phillips DM. JCAHO pain management standards are unveiled. Joint Commission on Accreditation of Healthcare Organizations[J]. JAMA, 2000, 284(4): 428－429.
[3]	徐建国. 疼痛药物治疗学[M]. 北京：人民卫生出版社，2007.
[4]	Li J, Chen J, Qin Q, et al. Chronic pain and its association with obesity among older adults in China[J]. Arch Gerontol Geriatr, 2018, 76: 12－18.
[5]	Jesus TS, Landry MD. Global need: including rehabilitation in health system strengthening[J]. Lancet, 2021, 397(10275): 665－666.
[6]	Dzierzewski JM, Ravyts S, Griffin SC, et al. Sleep and pain: the role of depression[J]. Curr Sleep Medicine Rep, 2019, 5(4): 173－180.
[7]	中华医学会骨科学分会关节外科学组. 骨关节炎诊疗指南(2018年版)[J]. 中华骨科杂志，2018, 38(12): 705－715.
[8]	中华医学会骨科学分会关节外科学组，中国医师协会骨科医师分会骨关节炎学组，国家老年疾病临床医学研究中心(湘雅医院), 等. 中国骨关节炎诊疗指南(2021年版)[J]. 中华骨科杂志，2021, 41(18): 1291－1314.
[9]	中国康复医学会脊柱脊髓专业委员会专家组．中国急/慢性非特异性腰背痛诊疗专家共识[J]. 中国脊柱脊髓杂志，2016, 26(12): 1134－1138.
[10]	Knezevic NN, Candido KD, Vlaeyen JWS, et al. Low back pain[J]. Lancet, 2021, 398(10294): 78－92.
[11]	马远征，王以朋，刘强，等. 中国老年骨质疏松症诊疗指南(2018)[J]. 中国骨质疏松杂志，2018, 24(12): 1541－1567.
[12]	何晓清，徐永清，朱跃良. 腰背痛流行病学进展[J]. 国际骨科学杂志，2008, 29(2): 115－116, 122.
[13]	康鹏德，黄泽宇，李庭，等. 肌肉骨骼系统慢性疼痛管理专家共识[J]. 中华骨与关节外科杂志，2020, 13(1): 8－16.
[14]	Saetung S, Ongphiphadhanakul B, Rajatanavin R. The relationship of an Asian-specific screening tool for osteoporosis to vertebral deformity and osteoporosis[J]. J Bone Miner Metab, 2008, 26(1): 47－52.
[15]	夏维波，章振林，林华，等. 原发性骨质疏松症诊疗指南(2017)[J]. 中国骨质疏松杂志，2019, 25(3): 281－309.
[16]	曹清明，王蔚婕，张琳，等. 中国居民平衡膳食模式的践行——《中国居民膳食指南(2022)》解读[J]. 食品与机械，2022, 38(6): 22－29.
[17]	国家卫生健康委员会疾病预防控制局，国家心血管病中心，中国医学科学院阜外医院，等. 中国高血压健康管理规范(2019)[J]. 中华心血管病杂志，2020, 48(1): 10－46.
[18]	章振林，夏维波，汪纯，等. 原发性骨质疏松症社区诊疗指导原则[J]. 中华骨质疏松和骨矿盐疾病杂志，2019, 12(1): 1－10.
[19]	Black DM, Rosen CJ. Clinical practice. Postmenopausal osteoporosis[J]. N Engl J Med, 2016, 374(3): 254－262.
[20]	Vannabouathong C, Bhandari M, Bedi A, et al. Nonoperative treatments for knee osteoarthritis: an evaluation of treatment characteristics and the intra-articular placebo effect: a systematic review[J/OL]. JBJS Rev, 2018, 6(7): e5. DOI: 10.2106/JBJS.RVW.17.00167.
[21]	张军，陆大江. 有氧运动结合抗阻力量训练对中年女性身体成分和骨密度的影响[J]. 中国老年学杂志，2016, 36(18): 4553－4556.
[22]	Karasavvidis T, Totlis T, Gilat R, et al. Platelet-rich plasma combined with hyaluronic acid improves pain and function compared with hyaluronic acid alone in knee osteoarthritis: a systematic review and meta-analysis[J]. Arthroscopy, 2021, 37(4): 1277－1287.
[23]	邢丹，吴海山，余楠生. 医用几丁糖在关节腔注射应用的专家共识(2018版)[J/CD]. 中华关节外科杂志(电子版), 2018, 12(2): 290－292.
[24]	Anil U, Markus DH, Hurley ET, et al. The efficacy of intra-articular injections in the treatment of knee osteoarthritis: a network meta-analysis of randomized controlled trials[J]. Knee, 2021, 32: 173－182.
[25]	Phillips M, Bhandari M, Grant J, et al. A systematic review of current clinical practice guidelines on intra-articular hyaluronic acid, corticosteroid, and platelet-rich plasma injection for knee osteoarthritis: an international perspective[J/OL]. Orthop J Sports Med, 2021, 9(8): 232596712110302. DOI: 10.1177/23259671211030272.
[26]	Sheean AJ, Anz AW, Bradley JP. Platelet-rich plasma: fundamentals and clinical applications[J]. Arthroscopy, 2021, 37(9): 2732－2734.
[27]	Garza JR, Campbell RE, Tjoumakaris FP, et al. Clinical efficacy of intra-articular mesenchymal stromal cells for the treatment of knee osteoarthritis: a double-blinded prospective randomized controlled clinical trial[J]. Am J Sports Med, 2020, 48(3): 588－598.
[28]	Li M, Cheng Q, Huo YN, et al. Efficacy of Yigu® versus Aclasta® in Chinese postmenopausal women with osteoporosis: a multicenter prospective study[J/OL]. Arch Osteoporos, 2022, 17(1): 14. DOI: 10.1007/s11657-021-01052-y.
[29]	Alin CK, Grahn-Kronhed AC, Uzunel E, et al. Wearing an activating spinal orthosis and physical training in women with osteoporosis and back pain: a postintervention follow-up study[J/OL]. Arch Rehabil Res Clin Transl, 2021, 3(4): 100154. DOI: 10.1016/j.arrct.2021.100154.
[30]	Nuti R, Brandi ML, Checchia G, et al. Guidelines for the management of osteoporosis and fragility fractures[J]. Intern Emerg Med, 2019, 14(1): 85－102.

Please choose a citation manager

Content to export